CTOs on the Move

Hs Pharma

www.hspharma.com

 
Hs Pharma is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lehigh Valley Technology

Lehigh Valley Technology is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SourceMark

A certified minority-owned business, SourceMark continues to focus on your needs to improve the lives of all patients, customers, and healthcare providers. Our clinical advisory groups are personally involved with the continued improvement of current p...

ABO Pharmaceuticals

ABO Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aphria

Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in Greenhouses, Aphria offers premium medical grade cannabis. Located in Leamington in Southwestern Ontario, the heart of the greenhouse-producing sector for plant and produce, Aphria is built from a lengthy background of greenhouse growing and business experience.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.